Business · 09/10/2026

European Medicines Agency Approves Modification to Paediatric Investigation Plan for Nilemdo

The European Medicines Agency (EMA) has made a decision on a modification to a Paediatric Investigation Plan (PIP) for Nilemdo, a medication containing bempedoic acid (ETC-1002), which is used to treat metabolism and nutrition disorders. The decision was made in response to a request from the manufacturer to modify the original PIP.